CohBar, Inc.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2007-01-01
- Employees
- 10
- Market Cap
- -
- Website
- http://www.cohbar.com
Clinical Trials
1
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
A Phase 1a/1b Study of CB4211 in Healthy Non-obese Subjects and Subjects With Nonalcoholic Fatty Liver Disease
- Conditions
- Nonalcoholic Fatty Liver Disease
- Interventions
- Drug: CB4211 Dose 1Drug: CB4211 Dose 3Drug: CB4211 Dose TBDDrug: CB4211 Dose 2Drug: CB4211 Dose 5Drug: CB4211 Dose 4Drug: CB4211 Dose 6Drug: Placebo
- First Posted Date
- 2019-06-26
- Last Posted Date
- 2021-05-11
- Lead Sponsor
- CohBar, Inc.
- Target Recruit Count
- 88
- Registration Number
- NCT03998514
- Locations
- 🇺🇸
ProScietno, Chula Vista, California, United States
🇺🇸Covance Clinical Research Unit Inc., Dallas, Texas, United States
🇺🇸The Texas Liver Institute, San Antonio, Texas, United States
News
Leading Biotech Companies Converge at Mitochondria-Targeted Drug Development Summit to Advance Therapeutic Pipeline
• Industry leaders from Stealth BioTherapeutics, Cohbar, and GenSight Biologics will gather at the exclusive Mitochondria-Targeted Drug Development Digital Summit to share breakthrough research developments. • The summit will showcase innovative approaches including Mitokinin's PINK1 activation for Parkinson's disease and Larimar Therapeutics' CTI-1601 protein replacement therapy for Friedreich's Ataxia. • Over 80 key industry experts will participate in 20+ hours of content and workshops, focusing on advancing therapeutics for mitochondrial and age-related diseases.